Showing 5461-5470 of 9753 results for "".
- Regenerative Medicine Breakthrough: Researchers Create BioPrinted Full Thickness Skinhttps://practicaldermatology.com/news/regenerative-medicine-breakthrough-researchers-create-bioprinted-full-thickness-skin/2462041/New bioprinted skin may accelerate wound healing, support healthy extracellular matrix remodeling, and aid in complete wound recovery, according to research out of the Wake Forest Institute for Regenerative Medicine (WFIRM). Available grafts are often temporary, or if permanent, h
- Study: Image-Guided Superficial Radiation Therapy Yields Superior 2-Year Recurrence Rates Compared to Mohshttps://practicaldermatology.com/news/study-image-guided-superficial-radiation-therapy-yields-superior-2-year-recurrence-rates-compared-to-mohs/2462035/Image-guided superficial radiation therapy (Image-Guided SRT, or IGSRT), bested Mohs micrographic surgery (MMS) for individuals with early stage nonmelanoma skin cancers (NMSCs). The study, which is the first to directly compare two-year recurrence probabilities of image-guided SRT to M
- Wound Repair Breakthrough: Protein Coacervates Engineered Into Adhesive for “Unprecedented” Skin Repair Speedhttps://practicaldermatology.com/news/wound-repair-breakthrough-protein-coacervates-engineered-into-adhesive-for-unprecedented-skin-repair-speed/2462032/A team of researchers from China is developing a novel biocomposite adhesive that may revolutionize wound management and tissue repair, according to a study in Engineering.
- Nevisense Detects Skin Barrier Damage In Skin Sampleshttps://practicaldermatology.com/news/nevisense-detects-skin-barrier-damage-in-skin-samples/2462031/Nevisense can measure skin barrier function in human excised skin samples, SciBase reports. For the study, Nevisense and its underlying Electrical Impedance Spectroscopy (EIS) technology were used to assess the effect of commercially available detergents on the skin barrier of mice
- Scrubbing Behind the Ears and Between the Toes May Help Keep These Skin Areas Healthyhttps://practicaldermatology.com/news/scrubbing-behind-the-ears-and-between-the-toes-may-help-keep-this-skin-healthy/2462030/Skin behind the ears and between the toes can host a collection of unhealthy microbes, according to a new study by a team at the George Washington University. Researchers at the GW Computational Biology Institute wanted to take a closer look at the skin microbiome of healthy
- DEF, SDPA Call Attention to Heart Health for World Heart Dayhttps://practicaldermatology.com/news/def-sdpa-call-attention-to-heart-health-for-world-heart-day/2462027/The Dermatology Education Foundation (DEF) and the Society of Dermatology Physician Assistants (SDPA) are calling on NPs and PAs in dermatology to take charge of their own health and support peers in recognition of World Heart Day on September 29, 2023. “As nurse practitioner
- Abeona Submits BLA for RDEB Treatmenthttps://practicaldermatology.com/news/abeona-submits-bla-for-rdeb-treatment/2462026/Abeona Therapeutics Inc. submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of EB-101, its investigational autologous, engineered cell therapy, as a treatment for patients with recessive dystrophic epidermolysis bullosa (RDEB). <
- Study: Test Kids With AD for Allergic Contact Dermatitishttps://practicaldermatology.com/news/study-test-kids-with-ad-for-allergic-contact-dermatitis/2462025/Children with atopic dermatitis may also need to be tested for allergic contact dermatitis, according to a new study in the
- ASDS: Dermatologists Remain the Primary Influencer for Patients’ Cosmetic Procedures, Skin Care Decisionshttps://practicaldermatology.com/news/asds-dermatologists-remain-the-primary-influencer-for-patients-cosmetic-procedures-skin-care-decisions/2462022/Board certified dermatologists hold the most sway when it comes to choosing a provider, cosmetic procedure, or skin care product, according to the
- Escient Pharmaceuticals Initiates Clinical Proof-of-Concept Study of EP262https://practicaldermatology.com/news/escient-pharmaceuticals-initiates-clinical-proof-of-concept-study-of-ep262/2462020/The first patient has been dosed in Escient Pharmaceuticals CALM-CIndU, an open label Phase 1b clinical proof-of-concept study of EP262, a first-in-class oral MRGPRX2 antagonist for chronic inducible urticaria. By blocking activation of MRGPRX2 and degranulation of mast cells,